Anika Therapeutics Inc ANIK

US Biotechnology

$19.28 ▲ +6.70% (+$1.21)

🎯 52W High ⬆️ Above Yest. High ⚡ High Volume

Open $18.33

Prev Close $18.07

Day Range $17.87 – $19.29

52W Range $7.87 – $19.29

Market Cap $258.02M

Beta 0.20

EPS (TTM) $-0.79

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	1985-05-16
Shares Out.	13,380,000
Website	anika.com/ ↗
Phone	13026365401
Employees	235
Revenue	$32.6M
Gross Profit	$21.2M
Net Income	$3.3M
Free Cash Flow	$562,000
Total Assets	$183.5M
Total Liabilities	$46.2M
Equity	$137.3M

About Anika Therapeutics Inc

Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.

Anika Therapeutics Inc is a publicly traded company under the ticker symbol ANIK on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.